Westminster, CO (July 3, 2013)—Surefire Medical, Inc. is pleased to announce that Gordon McLennan, MD, of the Cleveland Clinic and Fred Moeslein, MD, PhD of the University of Maryland Medical Center have joined the Company’s Scientific Advisory Board.

“We are extremely fortunate to benefit from both Dr. McLennan’s and Dr. Moeslein’s extensive clinical expertise in interventional radiology as we continue to develop new, first-in-class infusion systems that may enable the development of effective, minimally invasive treatments for cancer, obesity, prostate enlargement and other conditions,” said Surefire Medical President and CEO Jim Chomas.

Dr. McLennan*, author of more than 34 published articles, serves as Past Chair of the Society of Interventional Radiology (SIR) Foundation. He is a member of the Renal Network, Inc., the Radiological Society of North America, the Society of Interventional Radiology, the Cardiovascular and Interventional Radiology Society of Europe, the American Chemical society and the Association of University Radiologists. At the Cleveland Clinic he holds appointments in the Departments of Radiology, Biomedical Engineering and the renowned Taussig Cancer Center.

Dr. Moeslein currently serves as Interim Director, Division of Vascular and Interventional Radiology, at the University of Maryland School of Medicine. He is a member of the Society of Interventional Radiology, the American Medical Association, the American Academy of Sciences, the Radiological Society of North America, Inc., and the Cardiovascular and Interventional Radiological Society of Europe.

About Surefire Medical

Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets. Surefire’s infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue. For more information, please visit www.surefire.local.

 

* Dr. McLennan will receive stock options as a member of Surefire’s SAB.

Achievement

Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.